Anti-infective prophylaxis for primary immunodeficiencies

What is done in Italian primary immunodeficiency network centers (IPINet) and review of the literature

Viviana Moschese, B. Martire, A. Soresina, L. Chini, S. Graziani, E. Monteferrario, R. Bacchetta, C. Cancrini, M. Fiorilli, E. Gambineri, A. Pession, C. Pignata, I. Quinti, R. Rondelli, P. Rossi, A. G. Ugazio, A. Plebani, M. C. Pietrogrande

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Primary immunodeficiencies (PIDs) are rare diseases characterized by an increased susceptibility to infections. Early diagnosis and appropriate treatment are critical for reducing morbidity and mortality. Based on available data, the efficacy of antibiotic administration for the prophylaxis of infections remains uncertain, and recommendations supporting this practice are poor. The use of antimicrobial prophylaxis is mainly based on single institution-specific experience without controlled measurements of patient safety and quality health outcomes. To address this issue an Italian Network on Primary Immunodeficiencies (IPINet) has been set up in 1999 within the Italian Association of Pediatric Hematology and Oncology (AIEOP) to increase the awareness of these disorders among physicians. Further, diagnostic and treatment guideline recommendations have been established to standardize the best clinical assistance to all patients, including antibiotic prophylaxis, and for a national epidemiologic monitoring of PIDs. The aim of this review is not only to give a scientific update on the use of antimicrobial prophylaxis in selected congenital immunological disorders but also to draw a picture of this practice in the context of the Italian Primary Immunodeficiency Network (IPINet). Controlled multicenter studies are necessary to establish if, when and how you should start an efficacious antimicrobial prophylaxis.

Original languageEnglish
Pages (from-to)935-946
Number of pages12
JournalJournal of Biological Regulators and Homeostatic Agents
Volume27
Issue number4
Publication statusPublished - Oct 2013

Fingerprint

Antibiotic Prophylaxis
Epidemiological Monitoring
Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Hematology
Patient Safety
Rare Diseases
Infection
Multicenter Studies
Early Diagnosis
Guidelines
Pediatrics
Morbidity
Physicians
Mortality
Health
Therapeutics

Keywords

  • Antimicrobial prophylaxis
  • Infections
  • IPINet-AIEOP
  • Primary immunodeficiencies

ASJC Scopus subject areas

  • Oncology
  • Endocrinology, Diabetes and Metabolism
  • Physiology (medical)
  • Immunology and Allergy
  • Immunology
  • Endocrinology
  • Physiology
  • Cancer Research

Cite this

Anti-infective prophylaxis for primary immunodeficiencies : What is done in Italian primary immunodeficiency network centers (IPINet) and review of the literature. / Moschese, Viviana; Martire, B.; Soresina, A.; Chini, L.; Graziani, S.; Monteferrario, E.; Bacchetta, R.; Cancrini, C.; Fiorilli, M.; Gambineri, E.; Pession, A.; Pignata, C.; Quinti, I.; Rondelli, R.; Rossi, P.; Ugazio, A. G.; Plebani, A.; Pietrogrande, M. C.

In: Journal of Biological Regulators and Homeostatic Agents, Vol. 27, No. 4, 10.2013, p. 935-946.

Research output: Contribution to journalArticle

Moschese, V, Martire, B, Soresina, A, Chini, L, Graziani, S, Monteferrario, E, Bacchetta, R, Cancrini, C, Fiorilli, M, Gambineri, E, Pession, A, Pignata, C, Quinti, I, Rondelli, R, Rossi, P, Ugazio, AG, Plebani, A & Pietrogrande, MC 2013, 'Anti-infective prophylaxis for primary immunodeficiencies: What is done in Italian primary immunodeficiency network centers (IPINet) and review of the literature', Journal of Biological Regulators and Homeostatic Agents, vol. 27, no. 4, pp. 935-946.
Moschese, Viviana ; Martire, B. ; Soresina, A. ; Chini, L. ; Graziani, S. ; Monteferrario, E. ; Bacchetta, R. ; Cancrini, C. ; Fiorilli, M. ; Gambineri, E. ; Pession, A. ; Pignata, C. ; Quinti, I. ; Rondelli, R. ; Rossi, P. ; Ugazio, A. G. ; Plebani, A. ; Pietrogrande, M. C. / Anti-infective prophylaxis for primary immunodeficiencies : What is done in Italian primary immunodeficiency network centers (IPINet) and review of the literature. In: Journal of Biological Regulators and Homeostatic Agents. 2013 ; Vol. 27, No. 4. pp. 935-946.
@article{13f9d9d6e695435ab25721546dbac97f,
title = "Anti-infective prophylaxis for primary immunodeficiencies: What is done in Italian primary immunodeficiency network centers (IPINet) and review of the literature",
abstract = "Primary immunodeficiencies (PIDs) are rare diseases characterized by an increased susceptibility to infections. Early diagnosis and appropriate treatment are critical for reducing morbidity and mortality. Based on available data, the efficacy of antibiotic administration for the prophylaxis of infections remains uncertain, and recommendations supporting this practice are poor. The use of antimicrobial prophylaxis is mainly based on single institution-specific experience without controlled measurements of patient safety and quality health outcomes. To address this issue an Italian Network on Primary Immunodeficiencies (IPINet) has been set up in 1999 within the Italian Association of Pediatric Hematology and Oncology (AIEOP) to increase the awareness of these disorders among physicians. Further, diagnostic and treatment guideline recommendations have been established to standardize the best clinical assistance to all patients, including antibiotic prophylaxis, and for a national epidemiologic monitoring of PIDs. The aim of this review is not only to give a scientific update on the use of antimicrobial prophylaxis in selected congenital immunological disorders but also to draw a picture of this practice in the context of the Italian Primary Immunodeficiency Network (IPINet). Controlled multicenter studies are necessary to establish if, when and how you should start an efficacious antimicrobial prophylaxis.",
keywords = "Antimicrobial prophylaxis, Infections, IPINet-AIEOP, Primary immunodeficiencies",
author = "Viviana Moschese and B. Martire and A. Soresina and L. Chini and S. Graziani and E. Monteferrario and R. Bacchetta and C. Cancrini and M. Fiorilli and E. Gambineri and A. Pession and C. Pignata and I. Quinti and R. Rondelli and P. Rossi and Ugazio, {A. G.} and A. Plebani and Pietrogrande, {M. C.}",
year = "2013",
month = "10",
language = "English",
volume = "27",
pages = "935--946",
journal = "Journal of Biological Regulators and Homeostatic Agents",
issn = "0393-974X",
publisher = "Biolife s.a.s.",
number = "4",

}

TY - JOUR

T1 - Anti-infective prophylaxis for primary immunodeficiencies

T2 - What is done in Italian primary immunodeficiency network centers (IPINet) and review of the literature

AU - Moschese, Viviana

AU - Martire, B.

AU - Soresina, A.

AU - Chini, L.

AU - Graziani, S.

AU - Monteferrario, E.

AU - Bacchetta, R.

AU - Cancrini, C.

AU - Fiorilli, M.

AU - Gambineri, E.

AU - Pession, A.

AU - Pignata, C.

AU - Quinti, I.

AU - Rondelli, R.

AU - Rossi, P.

AU - Ugazio, A. G.

AU - Plebani, A.

AU - Pietrogrande, M. C.

PY - 2013/10

Y1 - 2013/10

N2 - Primary immunodeficiencies (PIDs) are rare diseases characterized by an increased susceptibility to infections. Early diagnosis and appropriate treatment are critical for reducing morbidity and mortality. Based on available data, the efficacy of antibiotic administration for the prophylaxis of infections remains uncertain, and recommendations supporting this practice are poor. The use of antimicrobial prophylaxis is mainly based on single institution-specific experience without controlled measurements of patient safety and quality health outcomes. To address this issue an Italian Network on Primary Immunodeficiencies (IPINet) has been set up in 1999 within the Italian Association of Pediatric Hematology and Oncology (AIEOP) to increase the awareness of these disorders among physicians. Further, diagnostic and treatment guideline recommendations have been established to standardize the best clinical assistance to all patients, including antibiotic prophylaxis, and for a national epidemiologic monitoring of PIDs. The aim of this review is not only to give a scientific update on the use of antimicrobial prophylaxis in selected congenital immunological disorders but also to draw a picture of this practice in the context of the Italian Primary Immunodeficiency Network (IPINet). Controlled multicenter studies are necessary to establish if, when and how you should start an efficacious antimicrobial prophylaxis.

AB - Primary immunodeficiencies (PIDs) are rare diseases characterized by an increased susceptibility to infections. Early diagnosis and appropriate treatment are critical for reducing morbidity and mortality. Based on available data, the efficacy of antibiotic administration for the prophylaxis of infections remains uncertain, and recommendations supporting this practice are poor. The use of antimicrobial prophylaxis is mainly based on single institution-specific experience without controlled measurements of patient safety and quality health outcomes. To address this issue an Italian Network on Primary Immunodeficiencies (IPINet) has been set up in 1999 within the Italian Association of Pediatric Hematology and Oncology (AIEOP) to increase the awareness of these disorders among physicians. Further, diagnostic and treatment guideline recommendations have been established to standardize the best clinical assistance to all patients, including antibiotic prophylaxis, and for a national epidemiologic monitoring of PIDs. The aim of this review is not only to give a scientific update on the use of antimicrobial prophylaxis in selected congenital immunological disorders but also to draw a picture of this practice in the context of the Italian Primary Immunodeficiency Network (IPINet). Controlled multicenter studies are necessary to establish if, when and how you should start an efficacious antimicrobial prophylaxis.

KW - Antimicrobial prophylaxis

KW - Infections

KW - IPINet-AIEOP

KW - Primary immunodeficiencies

UR - http://www.scopus.com/inward/record.url?scp=84893268997&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84893268997&partnerID=8YFLogxK

M3 - Article

VL - 27

SP - 935

EP - 946

JO - Journal of Biological Regulators and Homeostatic Agents

JF - Journal of Biological Regulators and Homeostatic Agents

SN - 0393-974X

IS - 4

ER -